What are the benefits of cognitive enhancers for Alzheimer's disease: Use of population impact measures

BMC Geriatrics

Volumn 7, Issue , 2007, Pages

  Gammanpila, Udaya P ^a   Burns, Alistair ^b   Heller, Richard F ^b   Purandare, Nitin ^b  

^a ROYAL OLDHAM HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLINESTERASE INHIBITOR; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ARTICLE; COGNITION; CONFIDENCE INTERVAL; DRUG COST; HEALTH SURVEY; HUMAN; HYPERTENSION; MENTAL DETERIORATION; POPULATION RESEARCH; POPULATION SIZE; PREVALENCE; UNITED KINGDOM; URBAN POPULATION; AGED; COMORBIDITY; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; RISK;

AGED; ALZHEIMER DISEASE; CAUSALITY; CHOLINESTERASE INHIBITORS; COMORBIDITY; ENGLAND; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; PREVALENCE; RISK;

EID: 38349064843     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-7-25     Document Type: Article

References (34)

1. Mild cognitive impairment in older people. A Burns M Zaudig, Lancet 2002 360 1963 1965 10.1016/S0140-6736(02)11920-9 12493278
2. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. F Forette ML Seux JA Staessen L Thijs WH Birkenhager MR Babarskiene S Babeanu A Bossini B Gil-Extremera X Girerd T Laks E Lilov V Moisseyev J Tuomilehto H Vanhanen J Webster Y Yodfat R Fagard, Lancet 1998 352 1347 1351 10.1016/S0140-6736(98)03086-4 9802273
3. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. F Forette ML Seux JA Staessen L Thijs MR Babarskiene S Babeanu A Bossini R Fagard B Gil-Extremera T Laks Z Kobalava C Sarti J Tuomilehto H Vanhanen J Webster Y Yodfat WH Birkenhager, Arch Intern Med 2002 162 2046 2052 10.1001/archinte.162.18.2046 12374512
4. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. B McGuinness S Todd P Passmore R Bullock, Cochrane Database Syst Rev 2006 CD004034 16625595
5. NICE guidelines on the use of Donepezil Rivastigmine and Galantamine for the treatment of Alzheimers Disease. National Institute for Health and Clinical Excellence, 2001
6. Dementia: supporting people and their carers in health and social care. National Institute for Health and Clinical Excellence, 2006 http://www.nice.org. uk/guidance/index.jsp?action=byID&o=10998
7. Preventing dementia. N Purandare C Ballard A Burns, Advances in psychiatric treatment 2005 11 176 183 10.1192/apt.11.3.176
8. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. M Etminan S Gill A Samii, Pharmacotherapy 2003 23 726 730 10.1592/phco.23.6.726.32184 12820814
9. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. SA Areosa EV Grimley, Cochrane Database Syst Rev 2002 CD003804 12519608
10. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. K Yaffe G Sawaya I Lieberburg D Grady, JAMA 1998 279 688 695 10.1001/jama.279.9.688 9496988
11. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. in V A Ruitenberg A Hofman LJ Launer CM Van Duijn T Stijnen MM Breteler BH Stricker, N Engl J Med 2001 345 1515 1521 10.1056/NEJMoa010178 11794217
12. Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. E Grasel J Wiltfang J Kornhuber, Dement Geriatr Cogn Disord 2003 15 115 125 10.1159/000068477 12584426
13. Disease impact number and population impact number: a population perspective to measures of risk and benefit. RF Heller AJ Dobson, BMJ 2000 321 950 952 11030691 10.1136/bmj.321.7266.950
14. Impact numbers in health policy decisions. J Attia JH Page RF Heller AJ Dobson, Journal of Epidemiology and Community Health 2002 56 600 605 10.1136/jech.56.8.600
15. Implementing guidelines in primary care: can population impact measures help? RF Heller R Edwards P McElduff, BMC Public Health 2003 3 7 7 12542840 10.1186/1471-2458-3-7
16. Prioritising between direct observation of therapy and case-finding interventions for tuberculosis: use of population impact measures. RF Heller I Gemmell R Edwards I Buchan S Awasthi JA Volmink, BMC Med 2006 4 35 17181867 10.1186/1741-7015-4-35
17. Using economic analyses for local priority setting: the population cost-impact approach. RF Heller I Gemmell EC Wilson R Fordham RD Smith, Appl Health Econ Health Policy 2006 5 45 54 10.2165/00148365-200605010-00006 16774292
18. Helping to prioritise interventions for depression and schizophrenia: use of Population Impact Measures. RF Heller I Gemmell L Patterson, Clin Pract Epidemol Ment Health 2006 2 3 16553956 10.1186/1745-0179-2-3
19. Innovations: evidence-based practices: establishing the evidence base for psychiatric services: estimating the impact on the population. RF Heller L Patterson, Psychiatr Serv 2006 57 1558 1560 10.1176/appi.ps.57.11.1558 17085602
20. Commentary: Relative treatment effects are consistent across the spectrum of underlying risks... usually. FA McAlister, International Journal of Epidemiology 2002 31 76 77 10.1093/ije/31.1.76 11914298
21. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England. N Purandare C Swarbrick A Fischer A Burns, Int J Geriatr Psychiatry 2006 21 961 964 10.1002/gps.1591 16927408
22. Health Survey for England 2003 Volume 2 Risk factors for cardiovascular disease. K Soproston P Primatesta, HMSO 2004 http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsStatistics/DH_4098712
23. The Number of Events Prevented in Your Population (NEPP). 2007 http://www.phsim.man.ac.uk/nepp/
24. Centre for Evidence Based Medicine stats calculator. 2007 http://www.cebm.utoronto.ca/practise/ca/statscal/
25. Worldwide prevalence and incidence of dementia. L Fratiglioni RD De H guero-Torres, Drugs Aging 1999 15 365 375 10.2165/00002512-199915050-00004 10600044
26. Global prevalence of dementia: a Delphi consensus study. CP Ferri M Prince C Brayne H Brodaty L Fratiglioni M Ganguli K Hall K Hasegawa H Hendrie Y Huang A Jorm C Mathers PR Menezes E Rimmer M Scazufca, Lancet 2005 366 2112 2117 10.1016/S0140-6736(05)67889-0 16360788
27. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. C Courtney D Farrell R Gray R Hills L Lynch E Sellwood S Edwards W Hardyman J Raftery P Crome C Lendon H Shaw P Bentham, Lancet 2004 363 2105 2115 10.1016/S0140-6736(04)16499-4 15220031
28. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. G Livingston C Katona, Int J Geriatr Psychiatry 2000 15 203 207 10.1002/(SICI)1099-1166(200003)15:3<203::AID- GPS100>3.0.CO;2-9 10713577
29. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. SL Rogers MR Farlow RS Doody R Mohs LT Friedhoff, Neurology 1998 50 136 145 9443470
30. Reaching the population with dementia drugs: what are the challenges? FE Matthews I McKeith J Bond C Brayne, Int J Geriatr Psychiatry 2007 22 627 631 10.1002/gps.1720 17136710
31. RF Heller, Evidence for population health Oxford, OUP 2005
32. Cognitive disability and direct care costs for elderly people. S Kavanagh M Knapp, Br J Psychiatry 1999 174 539 546 10616633
33. Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. E Souetre RM Thwaites HL Yeardley, Br J Psychiatry 1999 174 51 55 10211151
34. Donepezil for dementia due to Alzheimer's disease. J Birks RJ Harvey, Cochrane Database Syst Rev 2006 CD001190 16437430